Inhibition of acetylcholinesterase by the H2-receptor antagonist nizatidine. 1988

G Kounenis, and D Voutsas, and M Koutsoviti-Papadopoulou, and V Elezoglou
Department of Pharmacology, Veterinary Faculty, Aristotelian University of Thessaloniki, Greece.

The purpose of the present investigation was to study if the stimulating effect of nizatidine on the intestinal smooth muscle is related to the acetylcholinesterase activity. Isolated segments of guinea pig ileum were used in Tyrode solution at 37 degrees C. Nizatidine (from 3.2 x 10(-6) to 3.2 x 10(-4) M) exerted a concentration-dependent contractile effect on the guinea pig ileum. The average maximum activity (mean +/- S.E.M.) of nizatidine (3.2 x 10(-4) M) was 96.21 +/- 6.19% of the average maximum activity of neostigmine (3.2 x 10(-6) M). The acetylcholine-induced contractions (from 10(-8) to 3.2 x 10(-6) M) were augmented by nizatidine (from 10(-5) to 10(-4) M) in a similar way to that by neostigmine (from 10(-8) to 10(-7) M). The acetylcholine-induced contractions were prevented by acetylcholinesterase (0.1 unit/ml). This acetylcholinesterase activity was inhibited by nizatidine (from 10(-5) to 10(-4) M) and this inhibition was similar to that of neostigmine (from 10(-8) to 10(-7) M). These findings suggest that the stimulating effect of nizatidine on the intestinal smooth muscle of the guinea pig ileum could be explained by the inhibition of acetycholinesterase activity.

UI MeSH Term Description Entries
D007082 Ileum The distal and narrowest portion of the SMALL INTESTINE, between the JEJUNUM and the ILEOCECAL VALVE of the LARGE INTESTINE.
D008297 Male Males
D009388 Neostigmine A cholinesterase inhibitor used in the treatment of myasthenia gravis and to reverse the effects of muscle relaxants such as gallamine and tubocurarine. Neostigmine, unlike PHYSOSTIGMINE, does not cross the blood-brain barrier. Synstigmin,Neostigmine Bromide,Neostigmine Methylsulfate,Polstigmine,Proserine,Prostigmin,Prostigmine,Prozerin,Syntostigmine,Bromide, Neostigmine,Methylsulfate, Neostigmine
D002800 Cholinesterase Inhibitors Drugs that inhibit cholinesterases. The neurotransmitter ACETYLCHOLINE is rapidly hydrolyzed, and thereby inactivated, by cholinesterases. When cholinesterases are inhibited, the action of endogenously released acetylcholine at cholinergic synapses is potentiated. Cholinesterase inhibitors are widely used clinically for their potentiation of cholinergic inputs to the gastrointestinal tract and urinary bladder, the eye, and skeletal muscles; they are also used for their effects on the heart and the central nervous system. Acetylcholinesterase Inhibitor,Acetylcholinesterase Inhibitors,Anti-Cholinesterase,Anticholinesterase,Anticholinesterase Agent,Anticholinesterase Agents,Anticholinesterase Drug,Cholinesterase Inhibitor,Anti-Cholinesterases,Anticholinesterase Drugs,Anticholinesterases,Cholinesterase Inhibitors, Irreversible,Cholinesterase Inhibitors, Reversible,Agent, Anticholinesterase,Agents, Anticholinesterase,Anti Cholinesterase,Anti Cholinesterases,Drug, Anticholinesterase,Drugs, Anticholinesterase,Inhibitor, Acetylcholinesterase,Inhibitor, Cholinesterase,Inhibitors, Acetylcholinesterase,Inhibitors, Cholinesterase,Inhibitors, Irreversible Cholinesterase,Inhibitors, Reversible Cholinesterase,Irreversible Cholinesterase Inhibitors,Reversible Cholinesterase Inhibitors
D005260 Female Females
D006168 Guinea Pigs A common name used for the genus Cavia. The most common species is Cavia porcellus which is the domesticated guinea pig used for pets and biomedical research. Cavia,Cavia porcellus,Guinea Pig,Pig, Guinea,Pigs, Guinea
D006635 Histamine H2 Antagonists Drugs that selectively bind to but do not activate histamine H2 receptors, thereby blocking the actions of histamine. Their clinically most important action is the inhibition of acid secretion in the treatment of gastrointestinal ulcers. Smooth muscle may also be affected. Some drugs in this class have strong effects in the central nervous system, but these actions are not well understood. Antihistaminics, H2,H2 Receptor Blockader,Histamine H2 Antagonist,Histamine H2 Blocker,Histamine H2 Receptor Antagonist,Histamine H2 Receptor Antagonists,Histamine H2 Receptor Blockader,Histamine H2 Receptor Blockaders,Antagonists, Histamine H2,Blockaders, Histamine H2 Receptor,H2 Receptor Blockaders,Histamine H2 Blockers,Receptor Antagonists, Histamine H2,Receptor Blockaders, H2,Antagonist, Histamine H2,Blockader, H2 Receptor,Blockaders, H2 Receptor,Blocker, Histamine H2,Blockers, Histamine H2,H2 Antagonist, Histamine,H2 Antagonists, Histamine,H2 Antihistaminics,H2 Blocker, Histamine,H2 Blockers, Histamine,Receptor Blockader, H2
D000109 Acetylcholine A neurotransmitter found at neuromuscular junctions, autonomic ganglia, parasympathetic effector junctions, a subset of sympathetic effector junctions, and at many sites in the central nervous system. 2-(Acetyloxy)-N,N,N-trimethylethanaminium,Acetilcolina Cusi,Acetylcholine Bromide,Acetylcholine Chloride,Acetylcholine Fluoride,Acetylcholine Hydroxide,Acetylcholine Iodide,Acetylcholine L-Tartrate,Acetylcholine Perchlorate,Acetylcholine Picrate,Acetylcholine Picrate (1:1),Acetylcholine Sulfate (1:1),Bromoacetylcholine,Chloroacetylcholine,Miochol,Acetylcholine L Tartrate,Bromide, Acetylcholine,Cusi, Acetilcolina,Fluoride, Acetylcholine,Hydroxide, Acetylcholine,Iodide, Acetylcholine,L-Tartrate, Acetylcholine,Perchlorate, Acetylcholine
D000110 Acetylcholinesterase An enzyme that catalyzes the hydrolysis of ACETYLCHOLINE to CHOLINE and acetate. In the CNS, this enzyme plays a role in the function of peripheral neuromuscular junctions. EC 3.1.1.7. Acetylcholine Hydrolase,Acetylthiocholinesterase,Hydrolase, Acetylcholine
D000818 Animals Unicellular or multicellular, heterotrophic organisms, that have sensation and the power of voluntary movement. Under the older five kingdom paradigm, Animalia was one of the kingdoms. Under the modern three domain model, Animalia represents one of the many groups in the domain EUKARYOTA. Animal,Metazoa,Animalia

Related Publications

G Kounenis, and D Voutsas, and M Koutsoviti-Papadopoulou, and V Elezoglou
October 1986, Hepato-gastroenterology,
G Kounenis, and D Voutsas, and M Koutsoviti-Papadopoulou, and V Elezoglou
August 1987, Journal of clinical pharmacology,
G Kounenis, and D Voutsas, and M Koutsoviti-Papadopoulou, and V Elezoglou
July 1984, Nihon Shokakibyo Gakkai zasshi = The Japanese journal of gastro-enterology,
G Kounenis, and D Voutsas, and M Koutsoviti-Papadopoulou, and V Elezoglou
May 1993, British journal of clinical pharmacology,
G Kounenis, and D Voutsas, and M Koutsoviti-Papadopoulou, and V Elezoglou
March 1984, Zeitschrift fur Gastroenterologie,
G Kounenis, and D Voutsas, and M Koutsoviti-Papadopoulou, and V Elezoglou
February 1990, Toxicology and applied pharmacology,
G Kounenis, and D Voutsas, and M Koutsoviti-Papadopoulou, and V Elezoglou
January 2008, Modern rheumatology,
G Kounenis, and D Voutsas, and M Koutsoviti-Papadopoulou, and V Elezoglou
April 1993, Journal of clinical pharmacology,
G Kounenis, and D Voutsas, and M Koutsoviti-Papadopoulou, and V Elezoglou
January 1982, Lancet (London, England),
G Kounenis, and D Voutsas, and M Koutsoviti-Papadopoulou, and V Elezoglou
November 1987, Journal of pharmacobio-dynamics,
Copied contents to your clipboard!